» Articles » PMID: 19185577

Sall4 Regulates Cell Fate Decision in Fetal Hepatic Stem/progenitor Cells

Overview
Specialty Gastroenterology
Date 2009 Feb 3
PMID 19185577
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Fetal hepatic stem/progenitor cells, called hepatoblasts, differentiate into both hepatocytes and cholangiocytes. The molecular mechanisms regulating this lineage segmentation process remain unknown. Sall4 has been shown to be among the regulators of organogenesis, embryogenesis, maintenance of pluripotency, and early embryonic cell fate decisions in embryonic stem cells. The expression and functional roles of Sall4 during liver development have not been elucidated. We here provide their first description in hepatoblasts.

Methods: To investigate functions of Sall4 in fetal liver development, Dlk(+)CD45(-)Ter119(-) hepatoblasts derived from embryonic day 14 mouse livers were purified, and in vitro gain and loss of function analyses and in vivo transplantation analyses were performed using retrovirus- or lentivirus-mediated gene transfer.

Results: We demonstrated that Sall4 was expressed in fetal hepatoblasts but not adult hepatocytes. The expression level of Sall4 gradually fell during liver development. Overexpression of Sall4 in hepatoblasts significantly inhibited maturation induced by oncostatin M and extracellular matrix in vitro, as evidenced by morphologic changes and suppression of hepatic maturation marker gene expression. When bile duct-like structures were induced by collagen gel-embedded culture, overexpression of Sall4 markedly augmented size and number of cytokeratin19(+)-branching structures. Knockdown of Sall4 inhibited formation of these branching structures. With in vivo transplantation, Sall4 enhanced differentiation of cytokeratin19(+)-bile ducts derived from transplanted hepatoblasts.

Conclusions: These results suggest that Sall4 plays a crucial role in controlling the lineage commitment of hepatoblasts not only inhibiting their differentiation into hepatocytes but also driving their differentiation toward cholangiocytes.

Citing Articles

Emerging Insights into Sall4's Role in Cardiac Regenerative Medicine.

Yang J Cells. 2025; 14(3).

PMID: 39936946 PMC: 11817359. DOI: 10.3390/cells14030154.


gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras.

Kamioka H, Yogosawa S, Oikawa T, Aizawa D, Ueda K, Saeki C JHEP Rep. 2023; 5(7):100759.

PMID: 37333975 PMC: 10275997. DOI: 10.1016/j.jhepr.2023.100759.


SALL4 activates PI3K/AKT signaling pathway through targeting PTEN, thus facilitating migration, invasion and proliferation of hepatocellular carcinoma cells.

Tang Z, Zhao P, Zhang W, Zhang Q, Zhao M, Tan H Aging (Albany NY). 2022; 14(24):10081-10092.

PMID: 36575044 PMC: 9831741. DOI: 10.18632/aging.204446.


Ssu72-HNF4α signaling axis classify the transition from steatohepatitis to hepatocellular carcinoma.

Kim H, Yoon J, Jeon Y, Park E, Lee J, Chen S Cell Death Differ. 2021; 29(3):600-613.

PMID: 34616001 PMC: 8901687. DOI: 10.1038/s41418-021-00877-x.


Investigating higher-order interactions in single-cell data with scHOT.

Ghazanfar S, Lin Y, Su X, Lin D, Patrick E, Han Z Nat Methods. 2020; 17(8):799-806.

PMID: 32661426 PMC: 7610653. DOI: 10.1038/s41592-020-0885-x.